Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplantation approach results in disease-free survival probabilities of 90%, 84%, and 78% for class 1, 2, and 3 thalassemia patients, respectively. Because of disease advancement, adult thalassemia patients have a higher risk for transplant-related toxicity and a 65% cure rate. Patients without matched donors could benefit from haploidentical mother-to-child transplantation. There is a high cure rate for children with SCA who receive HSCT following myeloablative conditioning protocols. Novel non-myeloablative transplantation protocols could make HSCT available to adult SCA patients who were previously excluded from allogeneic stem cell transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bone Marrow Transplantation in Patients with Thalassemia
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S. M. T., Muretto, P., & Albertini, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220701 · Cited by 636 · cited 1×
“The influence of pretransplant characteristics on the outcome of transplantation was analyzed in 161 patients ,17 yr of age, who were all treated with exactly the same regimen (Storb et al. 1977; Lucarelli et al. 1990).”
MethodSelf-citationLong-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904971 · Cited by 455
World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies
Williams, T. N., & Weatherall, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011692 · Cited by 430
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease
Locatelli, F. (2003) · Blood · doi:10.1182/blood-2002-07-2090 · Cited by 386 · cited 1×
“…88% Class 3: 87% Adult: 66% Class 1–2: 85% Class 3: 82% Adult: 62% Lucarelli et al. 2008 68 MUD 79.3% 40% La Nasa et al. 2005a 33 Cord blood 100% 79% Locatelli et al. 2003 70 MSD/MRD 83% 73% Ghavamzadeh et al. 1997 49 Related: 28 Unrelated: 21 89% (all patients) Related: 82% Unrelated: 71%…”
InfluentialWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., et al. (2001) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2001.v7.pm11787529 · Cited by 324 · cited 1×
“Walters et al. (2001) observed stable MC in 13 out of 50 patients (26”
BackgroundIannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269 · cited 1×
“In a retrospective multicenter series, Iannone et al. (2003) described a non-myeloablative HSCT approach in six pediatric patients with SCD and one with thalassemia.”
BackgroundVermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260 · cited 1×
“The results of transplantation might be even better if HSCT were performed in children before the development of irreversible sickle vasculopathy-related complications (Vermylen et al. 1998; Lucarelli et al. 2011).”
BackgroundAPLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION
Donnall Thomas, E., Storb, R., Fefer, A., Slichter, S., Bryant, J., Dean Buckner, C., Neiman, P., Clift, R., Funk, D., & Lerner, K. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90292-9 · Cited by 250 · cited 1×
“Cyclophosphamide (CY) is a well-established agent for providing adequate immunosuppression for allogeneic engraftment (Thomas et al. 1972; Storb et al. 1991).”
Background
Cited by
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 337
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910182 · Cited by 332
Metadata
- Authors
- Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J.
- Affiliations
- University of Rome Tor Vergata (IT)
- Corresponding author
- Lucarelli, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-04-04
- Volume
- 2
- Issue
- 5
- Pages
- a011825-a011825
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3331690
- OpenAlex
- W2113456470
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 14 · 2023: 16 · 2022: 12 · 2021: 14 · 2020: 14 · 2019: 12 · 2018: 10 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 16 · 2013: 6 · 2012: 2
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematopoietic stem cell transplantation, thalassemia, sickle cell disease, allogeneic transplantation, risk stratification, transplant toxicity, haploidentical transplantation, myeloablative conditioning, nonmyeloablative conditioning, disease-free survival
- MeSH terms
- Adult, Anemia, Sickle Cell, Graft vs Host Disease, Humans, Thalassemia, Hematopoietic Stem Cell Transplantation, Living Donors, Myeloablative Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia. https://app.cochat.ai/papers/10.1101/cshperspect.a011825
- The paper
- Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012). Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a011825
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.